Videos

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

Matthew Robbins, MD: Headaches Associated With COVID-19

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

Articles

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic. 

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Matthew Robbins, MD: Residency During COVID-19

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

AHS

New content coming soon, please check back later.